For this position, the recruiting organisation is InnoSer in Leiden, The Netherlands. The selected candidate will be employed by InnoSer and will be embedded in the POLARIS consortium, with academic supervision and disease-specific expertise provided by Dr Rogier Min at the Amsterdam Leukodystrophy Center (ALC), Amsterdam UMC.

InnoSer Leiden
InnoSer is a European preclinical contract research organization (CRO) supporting biotechnology and pharmaceutical partners with tailored in vitro and in vivo research services. We work as an extension of our clients’ teams from study design to execution and data analysis to drive development decisions. With facilities in Belgium and the Netherlands, our services and disease models span multiple therapeutic areas, including neurology/neuroscience, oncology, nephrology, cardiometabolic disease and rare diseases. This position is based at our facility in the Netherlands (Leiden), where we focus on rare genetic diseases affecting the nervous system as well as neurodegenerative diseases, using in vivo mouse models.
This doctoral project will focus on the characterisation of leukodystrophy mouse models and the preclinical evaluation of promising proof-of-concept interventions. The project is strongly rooted in in vivo neuroscience and requires a candidate with clear affinity for animal research, behavioural and neurological phenotyping, and the responsible use of mouse models in translational research.
The candidate will perform longitudinal natural-history studies in leukodystrophy mouse models, in particular for megalencephalic leukoencephalopathy with subcortical cysts (MLC). These studies will use behavioural, neurological and disease-relevant readouts to define robust phenotypes and assess disease progression. A key part of the project will be the development of an automated EEG analysis pipeline for MLC mice, with the aim of identifying reliable EEG biomarkers that can support future preclinical therapy studies.
The mouse phenotypes generated in this project will be aligned with clinically relevant endpoints defined within the POLARIS consortium, strengthening the translational value of the models. The candidate will also test selected candidate therapies emerging from other POLARIS work packages in leukodystrophy models to assess proof-of-concept efficacy.
Planned secondments will provide hands-on experience with lipid nanoparticle delivery, as well as opportunities to engage with patients and families to better understand the diseases and the priorities of affected communities. The candidate will work at the interface of CRO-based preclinical research, academic leukodystrophy expertise and patient-oriented therapy development.
The position is primarily based at InnoSer in Leiden, with regular academic interaction with the Amsterdam Leukodystrophy Center in Amsterdam, including approximately one day per week at Amsterdam UMC. The academic embedding will be at the Amsterdam Leukodystrophy Center, with the anticipated PhD defence at the Faculty of Medicine, Vrije Universiteit Amsterdam.
Important, strict eligibility criteria according to MARIE SKLODOWSKA CURIE programs apply to applicants:
- You must not already hold a doctoral degree.
- At the time of the application deadline, you must have a Master’s degree and must not have resided or carried out your main activity (work, studies, etc.) in the Netherlands for more than 12 months in the three years prior to the contract start date.
- You will participate in the network-wide training programme of POLARIS, which includes (international) training activities and planned secondments with POLARIS partner organizations throughout the EU.
We are looking for a motivated candidate with a Master’s degree in life sciences, preferably neuroscience. You have relevant experience in in vivo mouse studies gained during internships or research projects. Experience with behavioural or neurological phenotyping, animal welfare principles and robust experimental design is considered an advantage. Formal certification for working with laboratory animals, such as FELASA or an equivalent qualification, is preferred.
You have a strong interest in translational neuroscience and rare disease research. You are motivated to work with mouse models to understand disease mechanisms and to evaluate candidate therapies. You are able to think critically about how preclinical readouts can be aligned with clinically meaningful endpoints.
Because the project includes EEG analysis and the development of an automated analysis pipeline, experience with scripting and data analysis, for example in R or Python, is an advantage. Candidates with a strong motivation to further develop these skills are also encouraged to apply.
You work accurately and reproducibly, have strong attention to detail and are able to plan and organise complex experimental work. You have an analytical mindset, good communication skills and the ability to collaborate across different research environments. You will interact with colleagues at InnoSer, Amsterdam UMC and other POLARIS partner organisations, and should be comfortable working in an interdisciplinary and international setting.
- A contract for 12 months, with the intention to extend for a total of 3 years;
- Salary, mobility allowance and benefits according to the applicable MSCA Doctoral Network and host-organisation rules;
- Embedding in the international POLARIS doctoral training network;
- Access to network-wide training activities, secondments and transferable-skills development;
- A challenging and translational research project at the interface of in vivo neuroscience, rare disease biology and preclinical therapy development;
- A collaborative and entrepreneurial working environment;
- An open and supportive team culture with opportunities for scientific and professional development.
- Non-EU/EEA/Swiss applicants require a valid residence permit to live and work in the Netherlands.
Applications for the doctoral positions have now closed. The selection process is currently ongoing, and applications are being reviewed by the recruiting institutions.
POLARIS is now moving into the next phase of its doctoral programme, which will bring together a new cohort of researchers working across disciplines and sectors to advance translational research in leukodystrophies.














